Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

NASH Core Curriculum: Highlights of the NASH Curriculum
  • CME
  • CE

Credits Available
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Registered Nurses: 0.5 Nursing contact hours
Pharmacists: 0.5 contact hours (0.05 CEUs)
Released: September 9, 2021 Expiration: September 8, 2022
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences
Novo Nordisk Inc.
Stephen Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Explain the common underlying causes of obesity, diabetes, and NASH
  • Identify at-risk patients with NAFLD/NASH who require evaluation for hepatic fibrosis
  • Describe imaging and clinical/laboratory tests that are being used to characterize NAFLD, NASH, and fibrosis
  • Apply best practices in the lifestyle and pharmacologic management of NASH
  • Critically evaluate the latest efficacy and safety data on emerging treatments for NASH, and their potential utility in NASH management

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Stephen Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC

Visiting Professor of Hepatology
Radcliffe Department of Medicine
University of Oxford
Oxford, United Kingdom
Medical Director, Pinnacle Clinical Research
President, Summit Clinical Research

Stephen A. Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC, has disclosed that he has received consulting fees from Akero, Altimmune, Alentis, Axcella, Chronwell, CiVi Biopharma, Echosens, Foresite Labs, Galectin, Genfit, Gilead Sciences, Hepion, Hightide, HistoIndex, Inipharm, Intercept, Madrigal, Medpace, Metacrine, NGM Bio, NorthSea, Novartis, Novo Nordisk, PathAI, Poxel, Luminal, Terns, Viking, and Sagimet; has received funds for research support from Axcella, Bristol-Myers Squibb, Cirius, Conatus, Hepion, Cymabay, Enyo, Galectin, Galmed, Genfit, Gilead Sciences, Hightide, Immuron, Intercept, Madrigal, Metacrine, NGM Bio, NorthSea, Novartis, Novo Nordisk, Pfizer, Second Genome, Tobira/Allergan, and Sagimet; and has stock ownership or equity in Akero, Chronwell, Galectin, Genfit, HistoIndex, Madrigal, Metacrine, NGM, NorthSea, and PathAI.

Staff

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Robin Black, PharmD, BCACP

Scientific Director

Robin Black, PharmD, BCACP, has no relevant conflicts of interest to report.
Ruth Cohen Cooper, CHCP

Vice President, Science and Strategy

Ruth Cohen Cooper, CHCP, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

The online activities are intended for hepatologists, gastroenterologists, endocrinologists, and other physicians, nurses, pharmacists, and healthcare professionals who manage individuals with or at risk for NASH.

Goal

The goal of this comprehensive program is to arm learners with foundational education in NASH pathogenesis, diagnosis, current recommended management, and emerging pharmacologic treatment strategies.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-173-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 70% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 09, 2021, through September 08, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Risk Factors and Screening
  • CME
  • CE

Loading...
Expert recap of highlights from the NASH Core Curriculum, including pathogenesis, risk factors, and current and emerging therapies for patients with NAFLD/NASH.
Stephen Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Registered Nurses: 0.5 Nursing contact hours
Pharmacists: 0.5 contact hours (0.05 CEUs)
Released: September 9, 2021 Expiration: September 8, 2022

This program is divided into several short segments that you can access using the Video Chapters menu.

Related Content

Expert insights on emerging NAFLD/NASH treatments from Dr. Stephen Harrison and Clinical Care Options (CCO)

Stephen Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 17, 2021 Expired: September 16, 2022

Video from CCO and Dr. Stephen Harrison highlighting take-home points about pathogenesis, risk, and treatment of NAFLD/NASH from the NASH Core Curriculum

Stephen Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: September 9, 2021 Expired: September 8, 2022

Downloadable slides from CCO and Dr. Stephen Harrison highlighting take-home points about pathogenesis, risk, and treatment of NAFLD/NASH from the NASH Core Curriculum

Stephen Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC Released: September 9, 2021

From Clinical Care Options (CCO) and Global Liver Institute: Easy-to-read reminders on why and how to look for NAFLD and NASH in your patients: FIB-4, VCTE, MRE, and more

Released: August 6, 2021

Video Chapters


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences
Novo Nordisk Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue